Le Lézard
Classified in: Ebola virus, Health, Science and technology, Covid-19 virus
Subject: MRR

Global Messenger RNA (mRNA) Vaccines & Therapeutics Markets, 2022-2023 & 2028: Rising Demand for Therapeutic Drugs and Vaccines for Ebola, influenza, HIV, and Other Viral Illnesses


DUBLIN, Jan. 6, 2023 /PRNewswire/ -- The "Messenger RNA (mRNA) Vaccines & Therapeutics Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Research_and_Markets_Logo

Global Messenger RNA (mRNA) Vaccines and Therapeutics Market was valued at US$ 11.63 Billion in 2022 and is expected to reach US$ 26.34 Billion by 2028

Messenger Ribonucleic Acid (mRNA) is a term that refers to a single protein-coding gene in the genome that conforms as the basis for protein synthesis in cells. mRNA vaccines and treatments are made in laboratories utilizing mammalian cells and have favorable immunological characteristics.

Infection prevention mRNA vaccines, infectious disease treatment mRNA vaccines, customized cancer therapy mRNA vaccines, and standardization of cancer treatment mRNA vaccines are frequent types of vaccinations and therapies. They are injected into the body to activate virus-detecting immunological sensors and cause the cells to generate viral antigen proteins. This improves B- and T-cell responses, which helps the body's immunity.

Global Messenger RNA (mRNA) Vaccines & Therapeutics Market Size will expand at a CAGR of 14.60% from 2022 to 2028

mRNA vaccines and treatments are generated employing new technologies that are more effective against infections, have higher potency, improved immunogenicity, and are relatively more cost-effective than conventional pharmaceuticals.

One of the critical factors propelling the development of the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market is the increased prevalence of medical disorders such as diabetes, TB, cancer, and cardiovascular diseases (CVDs).

In addition, the industry also benefits from rising demand for therapeutic drugs and vaccines for Ebola, influenza, HIV, and other viral illnesses.

Evolution of the Global Messenger RNA (mRNA) Vaccines & Therapeutics Industry amidst Pandemic

With the launch and widespread usage of mRNA vaccines and therapies for COVID-19, 2020 marked a watershed moment for mRNA technology platforms. As a result, the combined market valuation of mRNA platforms had increased fast by 2020.

The increase in market value reflects expectations that mRNA technology will give far more than the current COVID-19 preventive vaccines.

Global Messenger RNA (mRNA) Vaccines & Therapeutics Market Segmentation Analysis:

By Type, the market is bifurcated into Infection Prevention mRNA Vaccine, Infectious Disease Treatment mRNA Vaccine, Individualized Cancer Treatment mRNA Vaccine, and Standardization of Cancer Treatment mRNA Vaccine.

By Application, Cancer, Infectious Diseases, and Others are the major segments covered in our report. As per our estimates, Infectious Diseases hold a significant share in the market and are estimated to remain dominant throughout the forecasted period.

By End User, we have studied the market for hospitals, Clinics, Diagnostics Centers, and Others. As per our analysis, clinics and diagnostic centers are gaining traction with the advancement of technology applications. However, hospitals tend to remain dominant throughout the study period.

By Region, North America, Europe, Asia-Pacific, and Rest of the World. During the forecast period, North America is estimated to monopolize the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market. The market in North America is contrived by an increase in demand for COVID-19 mRNA vaccines, major players operating in the US, and an exponential rise in the number of COVID-19 cases in the US.

Key Players:

Pfizer, GlaxoSmithKline, Daiichi Sankyo Company, Limited, Intellia Therapeutics, Moderna Inc, CureVac N.V., Arcturus Therapeutics Holdings, and BioNTech are the prominent companies in the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market examined in our analysis.

In addition, we have discussed the competition landscape section of the study, which included an overview, the latest development strategies, and market revenue analysis of the above-mentioned worldwide companies. Surprisingly, the major firms invest in mRNA technologies since they can integrate numerous molecules into a therapeutic drug, which is a huge growth factor.

Key Players:

Company Insights:

Key Topics Covered:

1. Introduction

2. Research& Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities

5. Global Messenger RNA (mRNA) Vaccines & Therapeutics Market

6. Share Analysis - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market
6.1 By Type
6.2 By Application
6.3 By End User
6.4 By Region

7. Type - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market
7.1 Infection Prevention mRNA Vaccine
7.2 Infectious Disease Treatment mRNA Vaccine
7.3 Individualized Cancer Treatment mRNA Vaccine
7.4 Standardization of Cancer Treatment mRNA Vaccine

8. Application - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market
8.1 Cancer
8.2 Infectious Diseases
8.3 Others

9. End User - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market
9.1 Hospital
9.2 Clinics
9.3 Diagnostics Centers
9.4 Others

10. Region - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World

11. Key Players

For more information about this report visit https://www.researchandmarkets.com/r/l4smrn

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 00:01
The cost of living is Gen Zs' and millennials' top societal concern, but green shoots of optimism for the economy and their personal finances are emergingNearly nine in 10 Gen Zs and millennials say purpose is important to their job satisfaction and...

14 mai 2024
Sky Harbour Group Corporation ("SHG" or the "Company"), an aviation infrastructure company building the first nationwide network of Home-Basing campuses for business aircraft, announced the release of its unaudited financial results for the quarter...

14 mai 2024
Discovery Silver Corp. ("Discovery" or the "Company") today announced financial results for the three months ended March 31, 2024 ("Q1 2024"). The Company also provided a summary of key events since the beginning of 2024, including the release on...

14 mai 2024
Solar Alliance Energy Inc. (?Solar Alliance' or the ?Company') , a leading solar energy solutions provider focused on the commercial and industrial solar sector, is pleased to announced its intention to complete a non-brokered private placement of up...

14 mai 2024
Tetra Tech, Inc. , a leading provider of high-end consulting and engineering services in water, environment and sustainable infrastructure, hosted its inaugural Investor Day at Nasdaq's Global Headquarters in New York City on Tuesday, May 14, 2024....

14 mai 2024
Aeterna Zentaris Inc. ("Aeterna" or the "Company"), a specialty biopharmaceutical company...



News published on and distributed by: